GlassScriptPhysician profile
Dawn M Huff
NPI 1821082983
$1,387.53
in general payments reported to CMS, 2019-2025
30 companies · $264 in 2025
The $264 reported for 2025 was more than what a typical Women'S Health (Nurse Practitioner) provider received nationally (typical 2025 total: $123).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $435 · 2022: $305 · 2023: $210 · 2024: $174 · 2025: $264.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $647.26 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $166.72 | 2021-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $159.56 | 2021-2025 | |
| Hologic Sales and Service, LLC | $111.06 | 2021-2023 | Myosure Tissue Removal Device, Novasure, Acessa Provu System |
| Organon LLC | $97.68 | 2021-2023 | Nexplanon |
| Aspira Women'S Health INC | $88.33 | 2022-2025 | Ova1 |
| Mayne Pharma Commercial LLC | $81.12 | 2022-2025 | |
| Biogen, INC. | $70.26 | 2024-2025 | Zurzuvae |
| Coopersurgical, INC. | $66.08 | 2022-2024 | Paragard T 380a, Paragard T 380a |
| Daiichi Sankyo INC. | $59.76 | 2021 | |
| Amgen INC. | $40.21 | 2022 | |
| Astellas Pharma US INC | $36.99 | 2024-2025 | Veozah |
| Pfizer INC. | $36.63 | 2025 | |
| Avion Pharmaceuticals | $33.17 | 2021-2023 | Balcoltra |
| Exeltis, USA INC. | $30.67 | 2021-2024 | Slynd |
| Gynesonics, INC. | $30.34 | 2023-2024 | Sonata Sonography-Guided Transcervical Fibroid Ablation System |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Actelion Pharmaceuticals US, INC. | $28.66 | 2021 | |
| Scynexis, INC. | $26.66 | 2022 | |
| Merck Sharp & Dohme LLC | $25.11 | 2022 | |
| Mycovia Pharmaceuticals, INC. | $23.26 | 2023 | Vivjoa |
| Avanos Medical | $21.43 | 2025 | On-Q Pump and Accessories |
| Boston Scientific Corporation | $18.31 | 2021 | |
| Pacira Pharmaceuticals Incorporated | $17.84 | 2021 | |
| Agile Therapeutics, INC. | $16.77 | 2021 | |
| Millicent US INC | $16.23 | 2024 | Intrarosa, Femring |
| Shield Therapeutics INC | $15.55 | 2025 | |
| Seqirus USA INC | $14.68 | 2024 | Flucelvax, Fluad |
| Alydia Health | $14.66 | 2021 | |
| Becton, Dickinson and Company | $14.13 | 2022 | |
| Therapeuticsmd, INC. | $13.92 | 2021 | |
| Alfasigma USA, INC. | $11.74 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Dawn Huff listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.